The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, ...

Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 ...

Pfizer’s latest share move reflects renewed attention on its label expansion, research pipeline, dividend profile, and ...

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda ...

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...

The FINANCIAL — Pfizer Inc. on May 23 announced that the European Summary of Product Characteristics (SmPC) and Package Leaflet for CHAMPIX (varenicline) have been updated to include safety and ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 “Today’s announcement further supports our goal to bring vepdegestrant to ...